Royalty Report: Drugs, Pain, Therapeutic – Collection: 249736

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Pain
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Diabetes Treatment
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 249736

License Grant
For the Exclusive License. Licensor grants a non-transferable, sole and exclusive, even as to Licensor and its Affiliates, worldwide license, with the right to sublicense, under the Licensor Patent Rights and Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit the Licensed Compound and Licensed Product in the Field in the Territory.
License Property
The Licensed Compound means Bicifadine and any prodrugs, optical isomers, hydrates, solvates, salt forms and polymorphs of Bicifadine.

Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.

Field of Use
Field means the treatment of any diseases, disorders and conditions in humans, other than the treatment or amelioration of vasomotor symptoms caused by or occurring in relation to or connection with menopause or other female hormonal fluctuations in a patient undergoing treatment.

IPSCIO Record ID: 230815

License Grant
Licensor shall grant the Licensee of Ireland a non-exclusive license, including the right to grant sublicense, of the Licensor Intellectual Property solely in the Field and in particular to make, have made, import, use, offer for sale and sell the Products in the Territory.

Licensor shall grant a non-exclusive sublicense of Licensors interests and entitlements solely in the Field under another Agreement in the anothers Know-How and the anothers patent Rights relating to the Compounds in the Territory, with the right to grants sublicenses.

License Property
Compounds shall mean the Licensor compounds named 220,075 and 273,547, the rights to which were licensed by Licensor pursuant to the ACY Agreement.

Product 220,075 shall mean , the twice daily oral formulation(s} using the Intellectual Property and incorporating the compound 220,075 (bicifadine- analgesic) utilizing the Technologies.

Product 273,547 shall mean the once daily oral formulation using the Intellectual Property and incorporating the compound 273,547 (nonbenzodiazapinen anxiolytic) utilizing the Technologies.

Field of Use
Field shall mean the research, development and commercialization of oral Controlled Release formulations of the Products.

IP relates to a controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 28851

License Grant
The restated agreement amends among other items, the sales obligations in respect of bicifadine, ocinaplon and the Company's 216,303.
License Property
Bicifadine is for the treatment of pain.  Ocinaplon is for the treatment of anxiety. The Company's 216,303 is for the treatment of depression.

IPSCIO Record ID: 5599

License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and  granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI).  It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 5590

License Grant
We licensed from the Licensee, on an exclusive, worldwide basis, indiplon, bicifadine, ocinaplon and DOV 216,303 for any indication, including insomnia, pain, anxiety and depression.  We have the right to develop and commercialize these compounds, including the right to grant sublicenses to third parties, subject to the Licensee’s right of first refusal.
License Property
BICIFADINE
UNITED STATES

U.S. 4,196,120 – expires 4/1/97

U.S. 4,231,935 – expires 11/4/97

U.S. 4,435,419 – expires 7/1/01

USSN 08/122,856 – pending

USSN 08/414,180 – pending

CL 216,303

UNITED STATES

U.S. 4,196,120 – expires 4/1/97

U.S. 4,231,935 – expires 11/4/97

U.S. 4,435,419 – expires 7/1/01

USSN 08/122,856 – pending

USSN 08/414,180 – pending

CL 273,547

UNITED STATES

U.S. 4,521,422 – expires 6/23/03
4,196,120 Substituted 3-azabicyclo[3.1.0 hexanes, acid addition salts, method of use and method of preparation are described. The compounds have anxiolytic and analgesic activity.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 253915

License Grant
Licensor grants the Licensee, of England, an exclusive license, with the right to grant sublicenses, under the Licensor Patents and Licensor Know-How to develop, use, make, have made, offer for sale, sell, import, market, distribute and promote the Compound and Products, in each case solely in the Field in the Territory.

Licensee shall have a non-exclusive license, with the right to grant sublicenses, to use the Licensor Trademarks solely for market research and other similar activities to determine whether Licensee will use the Licensor Trademarks or Licensee Trademarks in connection with the commercialization and promotion of the Product in the Field in the Territory.

License Property
Licensor has developed a Transported Prodrugâ„¢ of gabapentin for the treatment of restless legs syndrome (RLS) and the management of neuropathic pain (which includes post-herpetic neuralgia and diabetic peripheral neuropathy.

The Compound shall mean that certain compound, referred to internally at Licensor as XP13512, and all esters, hydrates, metabolites [(excluding gabapentin), polymorphs, prodrugs of gabapentin], salts, solvates, isomers and/or mixtures of isomers thereof.

The patents are for the Compound Family,  Analog Prodrug Sustained Release Oral Dosage Form Families, Crystalline Form Family, Convergent Synthesis Family, Alternative Synthesis Method Families,  Therapeutic Use to treat RLS Family, Therapeutic Use to treat Hot Flashes Family,  Therapeutic Use to treat Incontinence Family,  Therapeutic Use to treat Premature Ejaculation Family,  Therapeutic Use to treat Vulvodynia Family,  Therapeutic Use to treat Tinnitus Family,  and,  Topical Composition/Use to treat Local Pain Family.

XP13512 is a patented, new chemical entity that is designed to improve upon the clinical utility of gabapentin by taking advantage of high-capacity transport mechanisms in the gut to improve absorption.

Field of Use
XP13512 is currently in Phase III development for Restless Legs Syndrome (RLS) and in Phase II development for neuropathic pain.

Restless legs syndrome (RLS) is a condition that causes an uncontrollable urge to move your legs, usually because of an uncomfortable sensation. It typically happens in the evening or nighttime hours when you're sitting or lying down. Moving eases the unpleasant feeling temporarily.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 222534

License Grant
Licensor grants an exclusive license, or sublicense, as the case may be, under the Licensor Patent Rights and Know-how, in each case with the right to grant sublicenses, to research, develop, make, have made, use, import, export, market, offer for sale, sell and have sold, Licensed Product in the Territory within the applicable Field.
License Property
The Compounds means SCH 619734 (Rolapitant) and SCH 900978.

The Licensed Product means any product comprising, incorporating or containing any Compound, or an alternate form of any Compound, including, but not limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of any Compound to the extent such alternate form is claimed in the Licensor Patent Rights.

Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management of nausea and vomiting experienced by cancer patients undergoing treatment with emetogenic chemotherapy. Phase II clinical testing of rolapitant for the prevention of nausea and vomiting in cancer patients treated with highly emetogenic chemotherapy demonstrated promising five-day activity following the administration of a single dose.

Field of Use
The Field means with respect to SCH 619734 (Rolapitant) all therapeutic, prophylactic, palliative and diagnostic uses in humans, and means, with respect to SCH 900978, treatment of nausea or vomiting of any cause; treatment of disease or treatment of symptoms or side effects of disease in oncology indications; treatment of side effects of oncology treatments or therapies; and (iv) any other supportive care indications in oncology.

IPSCIO Record ID: 240601

License Grant
The Licensor of Denmark and Licensee are engaged in the development, production, and commercialization of pharmaceutical products and possess information and technology relating to the manufacture, use, and formulation of such products.

The Licensor of Denmark grants to an exclusive, even as to Licensor; in the Field in the Exclusive Territory to use the Licensor Product Deliverables and investigational new drug, or IND, Deliverables to make, have made under contract, use, develop and have developed under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances, in each case during the Option Period solely in connection with the Initial Development Program.

Licensor grants an exclusive option during the Option Period to license the Licensed Technology for the research, development and Commercialization of Licensee Products on the terms set forth in this Agreement.

Licensor grants an exclusive, even as to Licensor, with the right to grant sublicenses, under the Licensed Technology to develop, have developed under contract, use, offer to sell, sell, have sold, distribute and import pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances in the Exclusive Territory in the Field.

Licensor grants an exclusive, except as to Licensor or its licensees or sublicensees, license, with the right to grant sublicenses, under the Licensed Technology to develop, have developed under contract, use, offer to sell, sell, have sold, distribute and import pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances in the Limited Territory in the Field.

Licensor grants an exclusive, even as to Licensor, license, with the right to grant sublicenses, under the Licensed Technology to make and have made under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances for the Field in the Exclusive Territory.

Licensor grants a non-exclusive, license under the Licensed Technology, with the right to grant sublicenses, to make and have made under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances for the Field outside the Exclusive Territory.

For the Isomer Option, Licensor grants a right of first refusal on an exclusive license, with the right to grant sublicenses, under any applicable Patent, Know-How or intellectual property other than Patents, Controlled by Licensor relating to any Isomer Product to develop, have developed under contract, make, have made under contract, use, offer to sell, sell, have sold, distribute and import such Isomer Product in the Field in the Exclusive Territory.

License Property
Single Entity Product means a pharmaceutical product containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance, and developed or manufactured by or on behalf of Licensee or Sublicensees using or referencing the Licensed Technology or any part thereof, or the use, manufacture or sale of which would, but for the licenses granted herein, infringe any Licensed Patents or intellectual property right other than Patents included in the Licensed Technology.

Combination Product means a pharmaceutical product containing Lomoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more additional active drug substances, and developed or manufactured by or on behalf of Licensee or Sublicensees using or referencing the Licensed Technology or any part thereof, or the use, manufacture or sale of which would, but for the licenses granted herein, infringe any Licensed Patents or intellectual property right other than Patents included in the Licensed Technology.

Isomer Product means a pharmaceutical product containing an isomer of Lornoxicam as either the single active drug substance or as an active drug substance in combination with one or more other active drug substances, developed solely by Licensor, and for which Licensor files an IND or equivalent filing in the Exclusive Territory within five years of the Effective Date.

Lornoxicam means the active drug substance known as lornoxicam, having the chemical structure set forth in this Agreement.

Lornoxicam, also known as chlortenoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties.

Field of Use
Lornoxicam is a potent analgesic pain reliever, which makes it an attractive candidate for combination therapy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.